| INTRODUCTION
The treatment of IBD in children has been revolutionised by the use of anti-tumour necrosis factor-α (anti-TNF) monoclonal antibody therapy. 1 There has been a rapid increase in the use of anti-TNF medications over the last 15 years (since initial adult licencing in 2003), with symptomatic control, intestinal healing, and a reasonable safety profile. 2, 3 Deep remission (mucosal healing) is increasingly seen as the end-point of treatment. 4 However modifying the natural history of IBD in childhood should also result in reduction in surgical resections (for both stricturing and penetrating disease), a reduction in nondiagnostic perianal procedures (abscess drainage, seton placement) and preservation of normal growth. 5 The long-term impact of anti-TNF medications on the rates of surgery before transition to adult services in paediatric IBD is uncertain. Previous data appear to suggest that anti-TNF therapy delays but not avoids the need for surgery in childhood. 6 A recent review of surgery in adult disease found no reduction in surgical resections in those treated with anti-TNF agents, although it was expected that the individuals with the most severe disease are both exposed to anti-TNF therapy and are at the highest risk of requiring surgery. 7 Other studies considered surgical rates at a population level; work from Rungoe et al comparing two cohorts 1979-1986 and 2003-2011 ) demonstrating a significant reduction in surgical rates for both
Crohn's disease and ulcerative colitis paralleled by an increase in anti-TNF medication. 8 However Lazarev et al 1 did not find a reduction in small bowel resection rates over time in adults with Crohn's disease, despite increased anti-TNF use. 9 The recent "Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn's disease" (LIRIC) trial in adults, comparing outcomes after randomised escalation to either anti-TNF therapy or limited ileocaecal resection in Crohn's disease, concluded that surgical resection remained a viable alternative to medical therapy. 10 There are potential drawbacks to long-term anti-TNF use in patients, including the risk of serious infections, immune reactions and malignancy, which must be considered and discussed when starting patients on therapy and reviewed during ongoing treatment in an open fashion. 3, 10, 11 In children, the rates of surgery vary depending on underlying diagnosis and severity of disease. 12, 13 In previous data from our Southern United Kingdom (Wessex) region (1997) (1998) (1999) (2000) (2001) (2002) (2003) (2004) (2005) (2006) (2007) (2008) (2009) (2010) (2011) (2012) (2013) (2014) , 9% of patients with ulcerative colitis underwent colectomy prior to transition to adult service. 13 Three other studies over a 25-year time period (from 1996) reported colectomy rates varying between 6% and 24%. [14] [15] [16] In Crohn's disease, 24% of Wessex patients underwent a surgical procedure during childhood (2002) (2003) (2004) (2005) (2006) (2007) (2008) (2009) (2010) (2011) (2012) . 12 This number was comparable with other studies reporting around 1/3 patients undergoing a surgical procedure during childhood. 17, 18 In contrast to the increasing incidence of disease, the rates of paediatric surgery have not been reported to change over time. 19, 20 The impact of increasing use of anti-TNF therapy on surgical procedure rates during childhood is important to guide use of these medications and understand prognoses for patients and families. In this study, we looked at surgical and anti-TNF data in the context of disease incidence and prevalence, over an 11-year period. We aimed to determine the relationship between anti-TNF prevalence and surgical resection rates. The number of patients under the care of the paediatric gastroenterology service was estimated for each year of the study (2007-2017) based on
| METHODS

1.
The number of years a patient was in paediatric care (calculated using age at diagnosis and transition to adult care before the 18th birthday). All patients in Southampton are transitioned by their 18th birthday based on the "Ready, Steady, Go" policy defined locally. 24 Patients attend joint clinic between the age of 17 and 18 years and it is not possible to list the precise age for transition of individual patients.
2.
Patients reaching the age of 18 years being removed from the analysis for the following year.
3.
The number of patients in paediatric care in our service in 2007 n = 198) and the number of patients diagnosed for each subsequent year (Table 1) . 19 From these data, the annual prevalence of anti-TNF-treated Kaplan-Meier survival curves were constructed using both surgical resection and anti-TNF therapy as outcome measures, with patients' data being censored at the point of transition to adult care.
Additional survival analysis was conducted for surgery (event) by grouping patients into those treated with anti-TNF and those not treated, survival was to surgery (event) or transition to adult care (censored). Statistical significance was considered P = <0.05. All analysis was with SPSS v24 (IBM).
This study was registered as a service evaluation project with University Hospital Southampton NHS foundation trust department of child health.
| RESULTS
All eligible children (n = 825) were included in the analysis (498 Crohn's disease, 272 ulcerative colitis, 55 IBDU), the mean age at diagnosis was 12.59 years (1.59-17.64 years), 327 (39.6%) patients were female. The number of patients under paediatric gastroenterology care increased from 198 in 2007 to 343 in 2017, in line with the increase in disease incidence. 19 A summary of the data can be seen in Table 1 .
| Anti-TNF therapy
The number of patients newly started on anti-TNF therapy increased Overall absolute numbers and rates are calculated for the entire cohort. ). Table 2 and Figure 1 .
There was a no significant correlation between time from diagnosis to starting anti-TNF therapy and year of study PCC = −0.57, P = 0.067). However, there was a significant positive correlation between time to starting anti-TNF and surgical resection rate per year PCC = 0.681, P = 0.021). Table 2 .
| Surgical resections
There were 91 surgical resections over the 11-year period. This 
| Crohn's disease and ulcerative colitis
The overall use of anti-TNF agents in Crohn's disease (136 patients, 27.3%) was greater than that in ulcerative colitis (27 patients, 9.9%, 
| Perianal surgery
There were 37 perianal surgical procedures performed on 20 patients over the 11-year period. There was no significant change in the perianal procedure rate from 2007 to 2017 (1.52%-2.33% respectively, R 2 = 0.281, P = 0.402).
| Survival analysis
A survival analysis of the entire cohort was performed for anti-TNF 
T A B L E 3
Stepwise backward multiple regression model. Dependant variable-surgical resection rate per year. Following application of all four models only anti-TNF prevalence was a significant predictor of surgical resection rate over the study period Despite the decrease in overall surgical resection across the entire cohort, there was no difference in surgical resection rates between patients treated with anti-TNF therapy and those not treated with anti-TNF therapy, which has been previously reported in other cohorts. 7, 25 Analysis of the paediatric RISK IBD cohort from North America concluded that early intervention with anti-TNF is the best predictor of improved remission rates, with this group also having better growth outcomes, although surgical resection rates were not reported. Time (years from diagnosis) F I G U R E 4 A, Kaplan-Meier plot for surgical resection in anti-TNF treated (blue) and untreated (red) patients. Patients were included until an event (surgical resection) or until transition to adult services (censored). There was no significant difference between groups, P = 0.412 (Log rank). B, Kaplan-Meier plot for surgical resection, for Crohn's disease, in anti-TNF treated (blue) and untreated (red) patients. Patients were included until an event (surgical resection) or until transition to adult services (censored). There was no significant difference between groups, P = 0.297 (Log rank). C, Kaplan-Meier plot for surgical resection, for ulcerative colitis, in anti-TNF treated (blue) and untreated (red) patients. Patients were included until an event (surgical resection) or until transition to adult services (censored).
There was a significant difference between groups, with those treated with anti-TNF at higher risk of surgery, P = 0.00001 (Log rank) Data on the indication for starting anti-TNF was not available.
Previous studies have reported a delay in time to surgery with anti-TNF therapy in adults, which is also evident in this paediatric cohort. 28 However multivariate linear regression analysis did not result in the increase in time to surgical resection being a significant predictor of reduction in surgical resection rate during childhood.
Univariate analysis significantly associated the reduction in time to starting anti-TNF with surgical resection rate, but this did not survive multivariate analysis. This does potentially support starting anti-TNF earlier to reduce surgical resection rates.
Whether the delay results in reduced surgery in the long term There is a trend towards top-down medicine when treating IBD in adult populations, with early initiation of anti-TNF therapy aiming to modify disease course. 43 Whilst this is not yet recommended in paediatric practice, the promise of reducing surgical resection rates with prompt initiation of anti-TNF therapy is one of the reasons leading to increased use. However it is important to remember not all patients will be at risk of requiring surgery, or of disease progression, and therefore not all require anti-TNF therapy. This is part of a complex risk-benefit strategy and discussion. There is the potential to both over-treat and for significant side-effects. Nevertheless, some will progress rapidly and early intervention appears to modify risk in at least a subset patients. 29, 44 Additional factors such as dose optimisation, concurrent immunosuppression, and nutritional strategies are likely provide additional benefits. 45, 46 Our survival analysis shows that the risk of surgery increases over time and is around 20% at 8 years. Similarly, those children remaining in paediatric care have a 30% chance of being prescribed an anti-TNF agent after 8 years. After 5 years in paediatric care around 25% of children will have been started on an anti-TNF agent, similar to previously reported data showing, at 3 years, a third of patients treated in North America were on an anti-TNF agent. 47 The promise of personalising therapy at diagnosis to start anti-TNF agents earlier where required, and prevent high-resection rates, may become a reality in the next 5-10 years through application of clinical and multi-omic data. 48, 49 Tools to predict and identify patients most likely to benefit from early anti-TNF therapy are now emerging, potentially providing the ability for the clinician to predict severe patients at risk of requiring surgery and modifying their risk at an early stage. improved staff training, and improved supportive therapy which we were unable to account for. Surgical decision-making was made by a team of four paediatric gastroenterologists, eight paediatric surgeons, and two adult surgeons reflecting shared decision-making over the 11 years study period. Additionally there is no well-established longitudinal disease severity score, describing disease severity over several years, preventing normalisation of data by disease severity.
| Conclusions
There is a statistically significant increase in the prevalence of anti-TNF therapy over the 11-year study period. Over the same time, there was a significant decrease in the surgical resection rate in paediatric IBD. These data suggest that anti-TNF therapy may be modifying the natural history of IBD in childhood. Progression to personalising therapy within paedi-
atric IBD now appears to be the next major challenge, balancing which patients would benefit from early introduction of anti-TNF therapy and those where an expectant approach can be adopted.
